Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis in Pediatric Patients: Results of the Phase III, Randomized, Placebo-Controlled PROTOSTAR Study

In adults, guselkumab, a selective IL-23 inhibitor targeting the p19 subunit, demonstrated substantial efficacy with a favorable safety profile in treating moderate-to-severe plaque psoriasis.